Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
Travere Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Travere Therapeutics's total debt was $22.60M at Sep 30, 2018.
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2019 | Sep 30, 2018 | $22.60M | – |
See a number that looks wrong?